Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 3,292 shares at $68.76 ($226K) on 2023-02-23, disclosed to the SEC on 2023-02-27.
Open-market sale of $226k APLS by Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.76 | 1,646 | $113K | 50.0% |
| 2 | $68.76 | 1,646 | $113K | 50.0% |
| Total | $68.76 avg | 3,292 | $226K | 100% |
| Filing → |
| APLS | SELL | 2025-01-14 | $8K | — | Filing → |
| APLS | SELL | 2024-12-27 | $2K | — | Filing → |
| APLS | SELL | 2024-01-31 | $145K | — | Filing → |